RLAY — Relay Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $1.23bn
- $542.00m
- $25.55m
- 71
- 11
- 32
- 31
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 356 | 678 | 958 | 999 | 750 |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | 82.7 | 4.94 | 5.22 | 0 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 361 | 770 | 976 | 1,020 | 770 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 31.7 | 28.8 | 27.3 | 75.4 | 68.9 |
Net Intangible Assets | |||||
Other Long Term Assets | |||||
Total Assets | 393 | 800 | 1,008 | 1,100 | 844 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 12 | 13.6 | 24.3 | 63.7 | 30.3 |
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 35.7 | 36.5 | 111 | 150 | 92 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 357 | 763 | 898 | 950 | 752 |
Total Liabilities & Shareholders' Equity | 393 | 800 | 1,008 | 1,100 | 844 |
Total Common Shares Outstanding |